Nektar Therapeutics (NKTR) Dividend History

Company News

• Nektar's (NKTR) Q2 Earnings Lag Estimates, Revenues Top

  Nektar Therapeutics reported a wider-than-expected loss in Q2 2024, despite a 14.6% increase in total revenues. The company's lead pipeline candidate, rezpegaldesleukin, is progressing through clinical trials for autoimmune and inflammatory diseases.

  Zacks Investment Research

  Featured Companies: EXAS LLY TRDA
• Nektar's (NKTR) Q1 Earnings and Revenues Surpass Estimates

  Nektar (NKTR) reports a narrower-than-expected loss in the first quarter of 2024 and tops revenue estimates.

  Zacks Investment Research

  Featured Companies: ANIP LGND
• Nektar Therapeutics Sees Something In The Data And Puts Its Drug To The Test

  Nektar Therapeutics' rezpegaldesleukin is now in two phase 2 studies, one in atopic dermatitis and one in alopecia areata. See why NKTR stock is a Hold.

  Seeking Alpha
• Nektar (NKTR) Up 7.5% Since Last Earnings Report: Can It Continue?

  Nektar (NKTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  Zacks Investment Research

  Featured Companies: TBPH
• Nektar (NKTR) Begins Phase IIb Study Rezpeg in Alopecia Areata

  The placebo-controlled, phase IIb study will investigate the efficacy and safety of Nektar's (NKTR) rezpeg in patients with severe to very severe alopecia areata.

  Zacks Investment Research

  Featured Companies: INDV LLY VNDA